MEDVi Pricing (2026): every published tier
MEDVi currently charges $179 first month, then $299/mo (first month, then $299/mo). We last verified this on MEDVi’s own site on 2026-08-14.
Every published MEDVi price
| Tier | Price | What that number means |
|---|---|---|
| Injectable Semaglutide (first month) | $179/mo | Introductory first-month rate for injectable compounded semaglutide |
| Injectable Semaglutide (ongoing) | $299/mo | Ongoing monthly rate for injectable compounded semaglutide |
| GLP-1 Tablets (starting) | $249/mo | Starting rate displayed on the current Katalys destination; the page does not publish the ongoing tablet rate |
What the first year actually costs
Computed honestly from the tiers above: $3,468 for year one (Year 1 uses the compounded semaglutide path on the current Katalys landing: $179 for month 1 + 11 × $299 refills = $3,468. MEDVi runs other offer variants and medication paths, so confirm the exact checkout rate for tablets, tirzepatide or brand-name medication.). Most comparison sites multiply the teaser by twelve; we do not.
MEDVi pricing questions
Can I switch from oral to injectable mid-treatment?
MEDVi markets both oral and injectable formats. Ask through the patient portal whether your clinician can change the prescription, and get the new first and renewal charges in writing before switching; the current landing does not establish that every format has the same price.
Does MEDVi offer tirzepatide?
Yes. MEDVi lists compounded tirzepatide in injectable and oral formats. Its current main Katalys destination does not publish an all-in medication-specific tirzepatide rate, and MEDVi runs offer-specific landing pages with different advertised prices, so confirm the exact first and renewal charges before paying.
Affiliate link, disclosed: MEDVi pays us a commission. It never changes a price on this page or a score anywhere on this site.
Full context, including who MEDVi is actually for: our independent MEDVi review.
How this price sits against all 54 programs we track: the cheapest verified GLP-1 programs and the machine-readable price index.
Comparing by molecule instead: semaglutide pricing across all providers.
Comparing by molecule instead: tirzepatide pricing across all providers.
Comparing by molecule instead: Wegovy access and pricing.
Comparing by molecule instead: Zepbound access and pricing.